Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Dallas, Texas 75204


This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.


Inclusion Criteria: - Postmenopausal female patient with histologically or cytologically confirmed breast cancer having progressed on Tamoxifen. - Advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/relapsed following > 8 weeks of treatment with Tamoxifen for advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of adjuvant treatment with Tamoxifen. - at least one measurable lesion Exclusion Criteria: - More than one previous chemotherapy and/or more than one hormonotherapy for advanced disease. - Previous hormonotherapy for advanced disease other than Tamoxifen. - Myocardial infarction within previous 6 mo



Primary Contact:

Study Director
Pfizer CT.gov Call Center

Backup Contact:


Location Contact:

Dallas, Texas 75204
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.